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Abstract
Background: Animal-free recombinant proteins provide a safe and effective alternative to tissue or serum-derived
products for both therapeutic and biomanufacturing applications. While recombinant insulin and albumin already
exist to replace their human counterparts in cell culture media, until recently there has been no equivalent for
serum transferrin.
Results: The first microbial system for the high-level secretion of a recombinant transferrin (rTf) has been
developed from Saccharomyces cerevisiae strains originally engineered for the commercial production of
recombinant human albumin (Novozymes’ Recombumin® USP-NF) and albumin fusion proteins (Novozymes’
albufuse®). A full-length non-N-linked glycosylated rTf was secreted at levels around ten-fold higher than from
commonly used laboratory strains. Modification of the yeast 2 μm-based expression vector to allow overexpression
of the ER chaperone, protein disulphide isomerase, further increased the secretion of rTf approximately twelve-fold
in high cell density fermentation. The rTf produced was functionally equivalent to plasma-derived transferrin.
Conclusions: A Saccharomyces cerevisiae expression system has enabled the cGMP manufacture of an animal-free
rTf for industrial cell culture application without the risk of prion and viral contamination, and provides a high-
quality platform for the development of transferrin-based therapeutics.
Background
Transferrin (Tf) is the major iron binding protein in
human plasma, responsible for the regulated delivery of
iron to cells. It is a monomeric glycoprotein (~80 kDa)
with the capacity to bind two ferric ions very tightly,
but reversibly. Transferrin consists of two globular lobes
(the N-lobe and C-lobe) each made up of two sub-
domains separated by a deep cleft, which contains the
binding site for a ferric ion and a synergistic carbonate
anion. In the vast majority of cell types iron is acquired
by the binding of iron-laden holo-transferrin to a spe-
cific transferrin receptor (TfR), followed by endocytosis
of the Fe3+/Tf/TfR complex. Iron is released in the
acidic conditions of the endosome, after which the Tf/
TfR complex is returned to the cell surface, from
where the iron-free apo-transferrin is released back
into circulation [1].
A current major use for plasma-derived transferrin is
in the preparation of media for the culture of mamma-
lian cells. The use of such media for the production of
pharmaceutical products requires stringent attention to
the source materials to control the risk of viral and
prion disease transmission. A recombinant microbial
source avoiding the use of mammalian-derived materials
provides an obvious advantage.
Therapeutic applications have also been proposed for
transferrin [2,3]. Treatment of the rare disease heredi-
tary atransferrinemia is the most obvious, where the
beneficial effects of transferrin infusion have been
described [4]. Recently, exogenous transferrin has been
used to ameliorate disease in b-thalassemic mice, where
improved erythropoiesis and red blood cell survival were
observed after treatment with transferrin [5]. This sug-
gests that transferrin therapy might provide a viable
alternative to blood transfusion and chelation therapy
* Correspondence: cjaf@novozymes.com
1Novozymes Biopharma UK Limited, Castle Court, 59 Castle Boulevard,
Nottingham, NG7 1FD, UK
Full list of author information is available at the end of the article
Finnis et al. Microbial Cell Factories 2010, 9:87
http://www.microbialcellfactories.com/content/9/1/87
© 2010 Finnis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
for treating human b-thalassemia and other diseases
with concurrent anemia and iron overload. Furthermore,
transferrin has been proposed as a means of reducing
free-iron concentrations and consequent oxidative
damage and infection risk [6-8]. Since transferrin is rela-
tively resistant to proteolytic degradation and the TfR is
abundant on gastrointestinal epithelial cells, transferrin
fusions and conjugates with GCSF, insulin and human
growth hormone have been studied for oral delivery of
therapeutic proteins [9,10]. The 7-10 day plasma half-
life of fully glycosylated transferrin in humans and the
14-15 day half-life reported for carbohydrate-deficient
transferrin also promise improved plasma half-life over
the unfused proteins in vivo [11,12]. Finally, overexpres-
sion of the TfR by many cancer cells has promoted
interest in the use of transferrin for tumor imaging and
targeted drug delivery [1].
Glycosylated and non-glycosylated recombinant
human transferrins have been secreted from baby ham-
ster kidney (BHK) cells. Both were shown to be fully
equivalent to the serum protein in iron binding and
interaction with cellular transferrin receptors, with gly-
cosylation being unimportant for transferrin function
in vitro [13]. However, expression from mammalian
cells does not meet the requirement for an inexpensive
source of recombinant transferrin, and may itself rely
upon an animal-derived source of transferrin in the cul-
ture media. Expression of full-length transferrin from
microbial sources has previously only been reported at
low levels ranging from 3-40 mg/L [14-16], although
transferrin production by recombinant plants has
recently been described at higher levels [17,18]. While
this could satisfy the need for an animal-free transferrin
source, MALDI MS analysis of the rice-derived transfer-
rin showed two peaks, with the mass of the predomi-
nant peak appearing 1,392 Da higher than the predicted
mass, suggesting post-translational modification.
Here we describe a highly productive yeast expression
system using baker’s yeast, Saccharomyces cerevisiae.
Successive rounds of chemical mutagenesis and selec-
tion, combined with deletion of specific endogenous
genes, have produced yeast strains with improved pro-
duct yield and quality [19-22]. These host strains were
combined with an episomal expression vector based
upon the highly stable yeast 2 μm plasmid [23]. The
expression vector contains the LEU2 selectable marker
and a recombinant protein expression cassette, compris-
ing the PRB1 promoter, a secretory leader, the coding
sequence of interest and the ADH1 terminator. S. cerevi-
siae transformed with such vectors contains only yeast
DNA and the coding sequence of interest. The yeast
expression system was initially developed for the high-
level secretion of recombinant human serum albumin
(rHA), but studies have shown that this system can
equally be used to express a diverse range of heterolo-
gous proteins. We have used this system as the basis for
the development of a recombinant transferrin produc-
tion platform.
Results and discussion
Removal of N-linked glycosylation sites in rTf reduces
product heterogeneity and allows visualization
by SDS-PAGE
Our initial transferrin expression vector (pDB2506) con-
tained the mature human transferrin (C1 variant)
sequence derived from a cDNA. Otherwise, the expres-
sion cassette (promoter, mHSA/MFa1-leader and termi-
nator) was the same as for rHA production [19].
Analysis of shake flask culture (SFC) supernatants of
DYB7 [pDB2506] by SDS-PAGE revealed a faint diffuse
protein band (Figure 1, Lanes A3 and B3), indicating
that product was secreted but that it was heterogeneous.
Yeast hyper-mannosylation at the two N-linked glycosy-
lation sites within the wild-type coding region was
expected to result in a mixture of glycoforms and diffi-
culty in visualization. Mutations were introduced to
eliminate both N-linked glycosylation sites, substituting
asparagine with glutamine at positions 413 and 611
of the mature protein. The molecular weight of non-
glycosylated transferrin is approximately 75 kDa. After
expression of rTf (N413Q, N611Q) from DYB7
[pDB2536], SDS-PAGE analysis showed a clearly visible
band for non-glycosylated transferrin (Figure 1, Lanes
A4 and B4). The identity of this band and the absence
of proteolytic fragments were confirmed by western
blotting (Figure 1B).
PDI1 overexpression increases rTf production
approximately ten-fold
High cell density fed-batch fermentation of DYB7
[pDB2536] produced a rTf yield of 0.17 g/L (Table 1).
This demonstrated the feasibility of rTf (N413Q,
N611Q) production in S. cerevisiae, but yields were low
when compared to a similar system expressing rHA.
Due to the known beneficial effects of PDI1 on protein
production in yeast [24,25] a new strain, DP9, was con-
structed with an additional copy of PDI1 integrated at
the PDI1-locus. This strain showed a significant increase
in rTf production (Figure 1, Lane C5). In view of the
high copy number and stability of whole 2 μm-derived
plasmids, insertion of PDI1 into the plasmid was consid-
ered for increasing the PDI1 gene copy number. While
it has previously been reported that insertion of PDI1
in the 2 μm plasmid was deleterious [24], we reasoned
that the problem might be related to both the architec-
ture of the 2 μm plasmid, consisting of several overlap-
ping transcription units, and the location of the PDI1
insertion site (Figure 2). Most potential insertion sites
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are within functional regions concerned with plasmid
amplification or partitioning. As a result, insertion of
“foreign” DNA is likely to disrupt one of these impor-
tant functions, thereby destabilizing the plasmid.
Novel sites were thus identified that did not have such
deleterious effects. The XcmI restriction site, down-
stream of REP2 in the inverted repeat region (Figure 2),
was one of several sites in the inverted repeat regions
that did not appear to destabilize the plasmid under
selective conditions (data not shown). We constructed
pDB2711 by inserting a copy of PDI1 at this XcmI site
with transcription in the same direction as REP2, in a
plasmid otherwise the same as pDB2536 (Figure 2).
DYB7 [pDB2711] gave a large increase in rTf expression
in shake flasks (Figure 1, Lane C6). A similar effect was
also seen in an alternative laboratory strain, JRY188,
showing that this effect is not strain-specific (Figure 1,
Lane C3). Fermentation titers of rTf produced from
strains with single, double and multicopy PDI1
demonstrated that the increased productivity observed
in SFC was also seen under production conditions,
resulting in rTf titers of around 1.5 g/L (Table 1).
Functional characterization demonstrates equivalence of
rTf and plasma-derived Tf
rTf derived from the strain DYB7 [pDB2711] was puri-
fied using a two-step ion-exchange chromatography
method for functional characterization. The purity of
the protein was assessed by SDS-PAGE (Figure 3). Ana-
lysis of the product by urea-PAGE indicated correct
iron binding with faster migration of the compact holo-
form compared to the open structure of the apo-form
(data not shown). The rTf product was also shown to
be functionally equivalent to plasma-derived transferrin
as a cell culture supplement [26]. Electron paramagnetic
resonance (EPR) was also used to confirm correct
co-ordination of the ferric ions in the rTf expressed
from S. cerevisiae [27].
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Figure 1 Shake flask analysis of rTf expression. (A) SDS-PAGE analysis for rTf with and without N-linked glycosylation. 30 μl of five-day
BMMD SFC supernatant was analyzed per lane by SDS-PAGE (4-12% Bis-Tris NuPAGE®, MOPS buffer, Invitrogen). Samples in lanes 2-4 were non-
reduced; the corresponding samples in lanes 6-8 were reduced. Track loadings were: Lanes 1 & 5) 5 μl SeeBlue® Plus2 protein standards
(Invitrogen) used for comparing relative migration of Tf samples only. Lanes 2 & 6) DYB7 [pSAC35] supernatant, negative control. Lanes 3 & 7)
DYB7 [pDB2506] supernatant, glycosylated transferrin. Lanes 4 & 8) DYB7 [pDB2536] supernatant, rTf (N413Q, N611Q). (B) Western blot analysis
for rTf with and without N-linked glycosylation. Lane 1) 5 μl MagicMark™ XP western protein standards (Invitrogen). All other lanes as for (A)
above. (C) Relative productivity of rTf (N413Q, N611Q) expression systems showing the effect of PDI1 copy number enhancement. 30 μl of five-
day BMMD SFC supernatant was analyzed per lane by non-reducing SDS-PAGE (4-12% Bis-Tris NuPAGE®, MOPS buffer, Invitrogen). Track loadings
were: Lane 1) SeeBlue® Plus2 protein standards (Invitrogen) used for comparing relative migration of Tf samples only. Lane 2) JRY188 [pDB2536]
with one genomic PDI1 gene. Lane 3) JRY188 [pDB2711] with multiple copies of PDI1. Lane 4) DYB7 [pDB2536] with one genomic PDI1 gene.
Lane 5) DP9 [pDB2536] with two genomic PDI1 genes. Lane 6) DYB7 [pDB2711] with multiple copies of PDI1.
Table 1 rTf production titers in high cell density fed-batch fermentations
Strain Number of fermentations Growth rate (h-1) pH Transferrin titer (g/L in supernatant)*
DYB7 [pDB2536] 1 0.07 6.5 0.17
DP9 [pDB2536] 2 0.07 6.5 0.39, 0.31
DYB7 [pDB2711] 2 0.07 6.5 1.48, 1.52
DYB7 [pDB3235] 2 0.06 6.2 0.24, 0.13
DYB7 [pDB3237] 2 0.06 6.2 2.25, 2.33
* Supernatant concentrations determined by HPLC.
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Leader sequence optimization results in rTf product with
the correct N-terminus
Despite the rTf product being functional, it was
observed as a double band on SDS-PAGE gels (Figure 4,
Lane 3), suggesting incomplete cleavage of the pre-pro
leader sequence. The secretory leader employed in the
construction of both pDB2536 and pDB2711 was a
combination of a modified HSA-pre and MFa1-
pro regions (with the sequence MKWVFIVSILF-
LFSSAYS↓RSLDKR↓) optimized for rHA secretion.
N-terminal sequence analysis of the rTf protein
secreted with this leader indicated that a proportion of
the product carried the propeptide-derived hexapeptide
extension (RSLDKR) - a result of incomplete cleavage
by Kex2p.
An alternative leader sequence was constructed by
deleting the coding region for the MFa1-derived pro-
sequence hexapeptide and leaving only the HSA-derived
pre-sequence terminating ...SSAYS (the “mHSA-leader”).
The rTf product (from pDB2929) appeared as a single
band when visualized by SDS-PAGE (Figure 4, Lane 4).
However, N-terminal sequence indicated that there was
still heterogeneity at the N-terminus, this time in the
form of a YS dipeptide extension, suggesting unspecific
cleavage by the yeast signal peptidase complexes. Conse-
quently, the invertase leader, from the S. cerevisiae Suc2
protein, was used for rTf secretion as this has been used
previously to produce recombinant proteins with the
correct N-termini in yeast [28]. Again a single band was
observed by SDS-PAGE (Figure 4, Lane 5), but in this
case the N-terminus was found to be both correct and
homogeneous. Analysis of SFC expression and protein
sequence data for the three different leader sequences
tested indicated that there was a trade-off between cor-
rect N-terminal cleavage and yield, with the invertase
leader showing a 23% reduction in titer compared to the
mHSA/MFa1 leader (Figure 5).
For the commercial production of rTf the invertase
leader sequence was used in combination with alterna-
tive N-linked glycosylation mutants (S415A, T613A as
opposed to N413Q, N611Q) and codon optimization of
the coding sequence. Fermentation of the resultant
strain, DYB7 [pDB3237], under optimized conditions
gave an average rTf titer of 2.29 g/L (Table 1).
Strain selection and PDI1 overexpression increased rTf
expression over fifty-fold in shake flask culture
In order to demonstrate the overall effect of strain selec-
tion and PDI1 overexpression, production of transferrin
was analyzed in two progenitor strains to DYB7, with or
without PDI1 on the expression plasmid (Figure 6). In
SFC, DYB7, in the absence of PDI1 overexpression,
showed more than a nine-fold increase in rTf produc-
tion levels over the original progenitor strain DB1.
Figure 2 A 2 μm-based plasmid for expression of rTf in yeast,
illustrating the rTf expression cassette, the PDI1 gene and
inserted E. coli DNA. Native 2 μm sequences (yellow) are shown
with gene transcripts (arrows). The S. cerevisiae LEU2 selectable
marker (yellow shaded) and transferrin gene (green/black/red) are
integrated between the STB locus and the origin of replication.
Bacterial sequences flanked by two repeat sequences containing the
recognition target for FLP-recombinase (blue) are integrated into an
inverted repeat (black triangles) causing them to be eliminated in
yeast. The PDI1 gene is inserted downstream of the REP2 gene.
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Figure 3 Purification of rTf from high cell density fed-batch
fermentation assessed by SDS-PAGE. 1 μg samples were
analyzed per lane by non-reducing SDS-PAGE (4-12% Bis-Tris
NuPAGE®, MOPS buffer, Invitrogen). Track loadings were: Lane 1)
SeeBlue® Plus2 protein standards (Invitrogen) used for comparing
relative migration of Tf samples only. Lane 2) DYB7 [pDB2711]
fermenter supernatant. Lane 3) DYB7 [pDB2711] SP-FF eluate. Lane
4) DYB7 [pDB2711] DE-FF eluate. Lane 5) human plasma-derived
transferrin.
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When combined, PDI1 overexpression and strain selec-
tion resulted in more than a fifty-fold increase in rTf
production. The increase observed with PDI1 overex-
pression in fermentation conditions was even greater
than in SFC (approximately five-fold), with titers
increasing more than twelve-fold (Table 1).
MS profiling of rTf mutants confirms reduced
glycosylation compared to plasma-derived transferrin
The rTf product derived from the strain DYB7
[pDB3237] was characterized by urea-PAGE and mass
spectrometry (Figure 7). As for the previous hexapep-
tide-extended form of rTf (N413Q, N611Q), urea-PAGE
demonstrated functional iron binding. MS data showed
the expected glycosylation differences between human
plasma-derived transferrin and the rTf (S415A, T613A).
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Figure 4 Effects of alternative leaders on rTf N-terminus. 3 μl of five-day BMMD SFC supernatant was analyzed per lane by non-reducing
SDS-PAGE (4-12% Bis-Tris NuPAGE®, MOPS buffer, Invitrogen). Track loadings were: Lane 1) SeeBlue® Plus2 protein standards (Invitrogen). Lane 2)
DYB7 [pSAC35] negative control. Lane 3) DYB7 [pDB2711] with the modified HSA-pre and MFa1-pro leader. Lane 4) DYB7 [pDB2929] with the
modified HSA-pre leader. Lane 5) DYB7 [pDB3557] with the S. cerevisiae invertase leader.
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Figure 5 Relative productivity of alternative leaders. rTf (N413Q,
N611Q) was expressed using three different leader sequences,
mHSA/MFa1, mHSA and invertase, using 2 μm expression plasmids
containing the PDI1 gene. Plasmids pDB2711, pDB2929 and
pDB3557 were transformed into the yeast strain DYB7. The
transformed yeast were inoculated at OD600 = 0.1 into BMMD SFC
and grown for five days, after which supernatant concentrations
were determined by HPLC. Error bars indicate standard deviations
(n = 4).
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Figure 6 Relative rTf (S415A, T613A) productivity of different
S. cerevisiae strains. The plasmids pDB3236 (-PDI1) and pDB3237
(+PDI1) were transformed into the strains DB1, DS569 and DYB7,
which form part of the mutagenized strain series developed for rHA
production. Yeast strains were inoculated at OD600 = 0.1 into BMMD
SFC and grown for five days, after which supernatant
concentrations were determined by HPLC. Error bars indicate
standard deviations (n = 4).
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The single predominant peak for the former (Figure 7B
(i)) is likely to consist of a range of glycoforms. Hetero-
geneity in the recombinant product exists only in the
form of O-linked glycosylation. The two peaks (Figure
7B (ii)) corresponded to the predicted mass of the non-
N-linked glycosylated transferrin and a form containing
a single hexose, probably resulting from yeast O-linked
mannosylation at serine-32 [29]. Functional testing by
receptor-mediated iron uptake (Table 2) and cell culture
supplementation experiments [30] indicated equivalence
between the plasma-derived and rTf analogue.
To control O-linked glycosylation, an additional trans-
ferrin mutant was produced to investigate whether ser-
ine-32 was the major site of O-linked glycosylation [29].
When analyzed by MS (Figure 7B (iii)), the rTf (S32A,
S415A, T613A) produced a single peak at the predicted
mass for non-glycosylated transferrin.
Conclusions
The high expression level (> 2 g/L) achieved in high cell
density fed-batch fermentation has enabled an econom-
ically viable process to be developed for production of a
high quality transferrin analogue for cell culture pur-
poses (Novozymes’ CellPrime™ rTransferrin AF). The
yeast-based fermentation process utilizes a chemically
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Figure 7 Characterization of rTf. (A) Urea gel analysis of rTf (S415A, T613A). 10 μg samples of purified recombinant apo-transferrin (Lane 1)
and holo-transferrin (Lane 2) derived from DYB7 [pDB3237] were separated on 6% TBE Urea PAGE (Invitrogen) and stained with Coomassie G250
(Pierce). (B) Deconvolved mass spectra from analysis of plasma-derived and rTf samples using ESI-TOF mass spectrometry. i) Plasma-derived
transferrin (Calbiochem), ii) rTf (S415A, T613A) derived from DYB7 [pDB3237], iii) rTf (S32A, S415A, T613A) derived from DYB7 [pDB3768].
Table 2 Dissociation constants (Kd) for transferrin
receptor-mediated iron-55 uptake and unspecific uptake
(Bmax) by K562 cells grown in vitro with recombinant and
plasma-derived transferrins
Transferrin source Kd (nM) Bmax (fmol/10
6 cells)
Human plasma Tf (Calbiochem) 105 ± 16 2668 ± 91
DYB7 [pDB3237] 104 ± 23 2543 ± 122
Errors indicate SEM (n = 3).
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defined medium consisting of only salts, trace elements,
sucrose, vitamins and ammonia. This fermentation pro-
cess is much less costly than equivalent mammalian cell
processes and, given the much higher yeast growth rate,
is also more productive in relation to capacity utiliza-
tion. In addition, the cGMP process avoids the use of
animal-derived materials, thereby eliminating the risk of
viral and prion contamination. Use of this rTf product
in mammalian cell culture instead of animal-derived
transferrin allows a simple elimination of these risks
while continuing to deliver iron to cells via the natural
mechanism of receptor-mediated endocytosis [26].
The system described here allows the production of
transferrin or transferrin-related products for therapeu-
tic use [1-5,7,9,11]. Proposed products include whole
transferrin, adducts or conjugates (e.g. to diphtheria
toxin for tumor therapy), and protein fusions. Other
members of the protein family such as lactoferrin could
be produced using similar approaches as well as deriva-
tives such as mutant transferrins or truncated proteins.
Transferrin fusions are of particular interest for two rea-
sons: Firstly, the Tf/TfR interaction may provide an
effective route for drug delivery to tumor cell targets;
and, secondly, fusion to transferrin may allow the devel-
opment of oral formulations for recombinant proteins.
Thus we anticipate that the system described above will
provide an enabling technology for a range of pharma-
ceutical products.
Methods
Plasmid and yeast strain construction
The human transferrin cDNA was excised from pcG13-
Tf (kindly supplied by Robert W Evans) as a 2.37-kb
PstI DNA fragment and cloned into the unique PstI site
of pBST+ [20] to create pDB2449. The 5’-end of the
transferrin cDNA was altered to replace the native
transferrin secretory leader sequence with a modified
version of the pre-pro HSA/MFa1 fusion leader
sequence [31] consisting of the amino acid sequence
MKWVFIVSILFLFSSAYSRSLDKR (referred to subse-
quently as the “mHSA/MFa1-leader”). Additionally, the
3’-end of the transferrin cDNA was modified to intro-
duce two TAA translation stop codons. The transferrin
sequence was then cloned between the PRB1 promoter
and the ADH1 terminator in the plasmid pDB2923. The
expression cassette from pDB2923 was subcloned as a
NotI fragment into the yeast episomal expression vector
pSAC35, in this case to produce pDB2506. To facilitate
the expression of non-N-linked glycosylated transferrin,
the asparagine residues at positions 413 and 611 were
replaced with glutamine residues (CAA codon) by PCR
mutagenesis to create the transferrin (N413Q, N611Q)
expression cassette in pDB2536.
For genomic integration of PDI1, a PstI-ScaI DNA
fragment containing the S. cerevisiae PDI1 gene [32]
was blunt ended and cloned into SmaI linearized
pUC19 to create plasmid pAYE561. A 2.94-kb KpnI
DNA fragment from pAYE561 (containing the PDI1
gene) was inserted into YIplac211 at the KpnI site to
create pDB2389. Plasmid pDB2389 was linearized with
Bsu36I for integration into the PDI1 locus of DYB7,
creating the strain DP9.
In order to insert the PDI1 gene onto the expression
plasmid, a linker containing a SmaI site was inserted
into pSAC35 [23] at the XcmI site downstream of the
REP2 gene to create plasmid pDB2688. A 1.9-kb S. cere-
visiae PDI1 fragment containing 212-bp upstream of the
start codon and 148-bp downstream of the termination
codon was then cloned, in the same orientation as
REP2, into the SmaI site to create plasmid pDB2690.
The expression cassette used to produce pDB2536 was
cloned, using NotI sites, into pDB2690 to create
pDB2711.
Leader sequence modifications resulting in the
“mHSA-leader”, lacking the final RSLDKR hexapeptide
of the “mHSA/MFa1-leader” or the yeast invertase lea-
der MLLQAFLFLLAGFAAKISA, were made to produce
pDB2929 and pDB3557 respectively. Further sequence
modifications to the transferrin sequence, including
codon optimization of the open reading frame and
reversed orientation of the NotI expression cassette,
resulted in production of pDB3237. pDB3768 contains
an S32A mutation in the transferrin coding sequence to
control O-glycosylation. To investigate the effect of
PDI1 overexpression, the NotI expression cassette from
pDB3237 was cloned into pSAC35, resulting in produc-
tion of pDB3235 (NotI cassette in same orientation as
LEU2) and pDB3236 (NotI cassette in opposite orienta-
tion to LEU2). NotI cassette orientation had no effect on
rTf production levels.
The yeast strains and expression plasmids used in this
study are listed in Table 3 and Table 4 respectively.
Culture conditions
Shake flask cultures with 10 ml BMMD (buffered mini-
mal medium dextrose [20] in 50 ml conical flasks) were
grown for five days at 30°C, 200 rpm. Shake flasks were
inoculated to OD600 = 0.1 with two-day starter cultures
of transformants grown in 10 ml BMMD in 50 ml coni-
cal flasks. Fed-batch fermentations were carried out in a
10 L Braun Biostat C fermenter at 30°C [33].
Purification procedure
A two-step ion-exchange chromatography procedure
was used to prepare rTf for protein characterization. An
SP-Sepharose Fast Flow column was used as the first
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step, followed by a DEAE-Sepharose Fast Flow column
as the second (GE Healthcare).
Urea gel electrophoresis
Urea gel electrophoresis was performed using a modifi-
cation of the procedure of Makey and Seal [34] with
commercial minigels (6% homogeneous TBE Urea, Invi-
trogen). Apo-transferrin was prepared by dialysis against
0.1 M citrate, 0.1 M acetate, 10 mM EDTA pH 4.5.
Reconstituted holo-transferrin was prepared from this
solution by addition of 10 μl 1 mM FeNTA (prepared
freshly as an equimolar solution of ferric chloride in dis-
odium nitrilotriacetic acid) to a 50 μl aliquot and
allowed to stand for 10 minutes to permit CO2 dissolu-
tion for completion of iron binding before electrophore-
tic analysis.
55Fe uptake competition in erythroleukemic K562 cells
For iron-55 uptake from labeled diferric transferrin,
K562 erythroleukemic cells cultured in RPMI cell cul-
ture medium under standard conditions (bicarbonate-
buffered, 5% CO2, antibiotics, 10% fetal calf serum) were
washed with serum-free medium containing HEPES-
buffer and 1 mg/ml of bovine serum albumin and used
at a concentration of 10 million cells/ml in this med-
ium. The samples tested were prepared as equimolar
concentrations of apo-transferrin. Transferrin was
loaded with iron according to a standard procedure
using ferric nitrilotriacetate as the iron source [35].
Increasing concentrations of plasma-derived transferrin
or the respective rTf sample (0, 25, 100, 200, 400, 800,
1600 nM), labeled with 55Fe, were mixed with 100 μl of
medium. The reaction was started by the addition of
100 μl of cell suspension. A second series of parallel
experiments was carried out in the presence of a hun-
dred-fold excess of unlabeled diferric transferrin to
account for unspecific binding. Since the counting data
showed that iron uptake was linear during the first 30
minutes, the reaction was always stopped after 25 min-
utes at 37°C by immersion in an ice-bath. Three 60 μl
aliquots of cell suspension were transferred to new
tubes, and the cells were centrifuged in the cold and
again after addition of an oil layer of diethylphthalate/
dibutylphthalate. The supernatant was removed, and the
cell pellet transferred into a counter vial and lysed with
0.5 M KOH + 1% Triton X-100. The lysates were neu-
tralized with 1 M HCl after overnight lysis, mixed with
Readysafe scintillation cocktail, and counted in the
Packard Liquid Scintillation Counter. The results are
presented as fmol 55Fe/million cells.
Protein characterization
N-terminal amino acid sequence analysis was carried
out by automated Edman degradation using an Applied
Biosystems 494 Procise® Protein Sequencer. Mass spec-
trometry samples were introduced into a hybrid quadru-
pole time-of-flight mass spectrometer (QqOaTOF,
Applied Biosystems, QSTAR-XL®), equipped with an
electrospray (IonSpray™) ion source in positive ion
mode, using flow injection analysis (FIA), and, typically,
1 minute of spectral scans were averaged.
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Table 3 Yeast strains used in this work
Strain Description/genotype Reference
JRY188 cir0 MATa, leu2-3, leu2-112, ura3-52, trp1, his4, sir3, rme, GAL [36]
DB1 cir0 MATa, leu2-3, leu2-112 [19]
DS569 rHA-overproducing strain derived from DB1 by chemical mutagenesis. Known genotype: cir0 MATa, leu2-3, leu2-112 [19,20]
DYB7 rHA-overproducing strain derived from DS569 by chemical mutagenesis. Known genotype: cir0 MATa, leu2-3, leu2-112 ubc4 ura3
yap3::URA3 lys2 hsp150::LYS2
[37]
DP9 DYB7 with PDI1, URA3 and YIplac211 integrated at the PDI1 locus This work
Table 4 Description of plasmids used in development of
the rTf expression system
Plasmid Description
pSAC35 2 μm-derived yeast episomal expression vector
pDB2506 pSAC35 with mHSA/MFa1-leader-rTf cassette at NotI site
pDB2536 pSAC35 with mHSA/MFa1-leader-rTf (N413Q, N611Q) cassette
at NotI site
pDB2690 pSAC35 with PDI1 inserted at XcmI site after REP2
pDB2711 pDB2690 with mHSA/MFa1-leader-rTf (N413Q, N611Q)
cassette at NotI site
pDB2929 pDB2690 with mHSA-leader-rTf (N413Q, N611Q) at NotI site
pDB3557 pDB2690 with invertase-leader-rTf (N413Q, N611Q) at NotI
site
pDB3237 pDB2690 with invertase-leader-rTf (S415A, T613A) at NotI site
pDB3768 pDB2690 with invertase-leader-rTf (S32A, S415A, T613A) at
NotI site
pDB3235 pSAC35 with invertase-leader-rTf (S415A, T613A) at NotI site
pDB3236 pSAC35 with invertase-leader-rTf (S415A, T613A) at NotI site
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